Nurix Therapeutics stock (US67079U1007): Analysts see 144% upside potential

Nurix Therapeutics (NRIX) shares have shown volatility with recent prices around $11-16, while 18 Wall Street analysts project an average price target of $27.07, implying 144% upside from recent levels, according to MarketBeat data as of October 2025.

Nurix Therapeutics, a clinical-stage biopharmaceutical company, has garnered attention from Wall Street analysts who set an average 12-month price target of $27.07 for its shares, representing a potential 144.06% upside from the $11.09 closing price on October 24, 2025, MarketBeat as of 10/24/2025. The consensus rating is 'Moderate Buy' based on input from 18 analysts, with targets ranging from $15 to $35. Recent trading saw the stock at $14.33 with a market cap of $1.45B, per Robinhood data.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Nurix Therapeutics, Inc.
• Sector/industry: Biopharmaceuticals
• Headquarters/country: United States
• Core markets: Oncology, inflammatory diseases
• Key revenue drivers: Small molecule therapies, protein modulation
• Home exchange/listing venue: Nasdaq (NRIX)
• Trading currency: USD

Nurix Therapeutics: core business model

Nurix Therapeutics develops small molecule and antibody therapies targeting cellular protein levels to treat cancer and inflammatory diseases. The company focuses on protein modulation technologies, including degraders that eliminate disease-causing proteins. Listed on Nasdaq under ticker NRIX, Nurix advances a pipeline of candidates in clinical trials, relevant to US investors via its exposure to the biotech sector and potential FDA approvals.

Main revenue and product drivers for Nurix Therapeutics

Nurix's revenue stems from collaborations and milestones in its drug discovery platform. Key programs target oncology indications, with protein degradation as a novel mechanism. The stock traded at $14.33 on Nasdaq as of recent data from Robinhood as of 11/19/2025, reflecting volatility typical in clinical-stage biopharma with no approved products yet.

Industry trends and competitive position

The protein degradation field is gaining traction as biotech firms innovate beyond traditional inhibitors. Nurix competes with players like Arvinas in targeted protein degraders for oncology. US market leadership in biotech funding supports Nurix's development, with its Nasdaq listing providing liquidity for American investors tracking novel modalities.

Why Nurix Therapeutics matters for US investors

As a Nasdaq-listed biotech, Nurix offers US investors access to cutting-edge protein modulation therapies amid rising demand for precision oncology treatments. Its pipeline progress could align with FDA priorities, impacting portfolios focused on innovative health tech.

Conclusion

Nurix Therapeutics continues to advance its protein degradation platform amid analyst optimism for substantial upside. Recent price action shows volatility, with strong buy signals from some technical views, though long-term averages suggest caution. Investors monitor clinical milestones for potential catalysts in this innovative biotech space.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.